Design,Synthesis,and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates

Abstract

A series of new hydroxamate derivatives of lupane triterpenoids has been designed and successfully synthesized. The synthesized compounds were evaluated for their in vitro antitumor activity using the 3-[4,5-dimethylthiazol-2-yl]−2,5-diphenyltetrazolium bromide-based assay against the human cancer cell lines KB and HepG2. Most of these derivatives possess at least moderate cytotoxic activity and the hydroxamate derivative compounds 3c, 3e, 7a, and 15b could be lead compounds for further optimization to develop novel anticancer agents.

Keywords

triterpenoid betulin betulinic acid hydroxamate cytotoxic activity

Introduction

Cancer is a dangerous disease which caused about 9.6 million deaths in 2018.¹ In recent decades, there has been a lot of research and development on new anticancer drugs, but there is still an urgent need for the further search and development of new improved drugs to target the inhibition of cancer cells. Many studies have shown that the molecular pathways are related to the cellular epigenome,^2
-4 and their dysregulation has an effect on cancer cells.^5
-7

Histone deacetylases (HDACs) are enzymes that are known to be overexpressed in cancer cell lines,^8

-13 and hydroxamate has been recognized as a zinc-binding group in the molecular structure of HDAC inhibitors. Hydroxamic acids have also been considered in the design for cancer treatment.^14

-17 Lead compounds of this class were approved by the Food and Drug Administration for cancer treatment, such as Zolinza (SAHA) (Figure 1) for the treatment of cutaneous T-cell lymphoma,¹⁸ Panobinostat for multiple myeloma¹⁹ in 2006, and Belinostat (PXD101) for peripheral T-cell lymphoma²⁰ in 2014; CUDC-101, Trichostatin A, and Oxamflatin (Figure 1) are currently undergoing clinical trials against different cancer cell lines.²¹ Therefore, hydroxamate derivatives have been designed and synthesized as a promising class of anticancer agents.^22,23

Figure 1

Structures of some histone deacetylase inhibitors.

Some lupane triterpenoids, such as betulin, betulinic acid, and its derivatives, have attracted considerable attention in recent years because of their activities against cancer cell lines.^24

-28 Reports have been rather limited so far on the combination of a triterpenoid and hydroxamate into single molecules, as well as their screening for anticancer activity. After considering the biological potential of such compounds, we decided to construct novel triterpenoid derived hydroxamates with the expectation of their potential use as anticancer agents. Therefore, in this study, a series of novel lupane derived hydroxamates were designed and synthesized at the C-28 position of the triterpenoid. The synthesized compounds were evaluated for their cytotoxic activity against 2 human cancer cell lines (KB and HepG2).

Results and Discussion

Chemistry

In this study, the conjugates of betulin derivatives with either hydroxylammonium chloride (NH₂OH.HCl) or N,O-dimethylhydroxylammonium chloride (HNMeOMe.HCl) 3a-f were synthesized following the synthetic procedure illustrated in Scheme 1. In the first step, betulin (1) was reacted with acid anhydride in dichloromethane in the presence of triethylamine (TEA) at room temperature for 24 hours to give the key intermediates 28-O-acylbetulins 2a-d,²⁹ which were then coupled with either NH₂OH.HCl or HNMeOMe.HCl in dimethylformamide (DMF) in the presence of 1 equiv benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and 2 equiv 4-dimethylaminopyridine (DMAP) at room temperature for 15 hours to give the targeted compounds 3a-f.

Scheme 1

Synthesis of hydroxamates 3a-f from betulin derivatives. Reagents and conditions: (a) 4 equiv anhydride, 1.2 equiv Et₃N, dichloromethane, room temperature (rt), 24 hours; (b) 2 equiv hydroxylammonium chloride, 1 equiv BOP, 2 equiv 4-dimethylaminopyridine (DMAP), dimethylformamide (DMF), rt, 15 hours; (c) 2 equiv N,O-dimethylhydroxylammonium chloride, 1 equiv BOP, 2 equiv DMAP, DMF, rt, 15 hours.

Analogously, the reaction of 3β acetoxy-21-oxolup-18-ene-28-oic acid (4) and betulinic acid (8) with 6-aminohexanoic acid in DMF in the presence of BOP/DMAP (1:2) at room temperature for 24 hours gave the acid intermediates 6 and 9 (Scheme 2, Scheme 3, Scheme 2, Scheme 3). Then, compounds 4, 6, and 9 were coupled with NH₂OH.HCl and HNMeOMe.HCl in the presence of BOP and DMAP to afford the targeted compounds 5a,b, 7a,b, and 10a,b, respectively (Scheme 2, Scheme 3, Scheme 2, Scheme 3, Supplemental Figures S1-S12).

Scheme 2

Synthesis of hydroxamates 5a,b and 7a,b. Reagents and conditions:(a) 2 equiv hydroxylammonium chloride, 1 equiv BOP, 2 equiv 4-dimethylaminopyridine (DMAP), dimethylformamide (DMF), room temperature (rt), 15 hours; (b) 2 equiv N,O-dimethylhydroxylammonium chloride, 1 equiv BOP, 2 equiv DMAP, DMF, rt, 15 hours; (c) 2 equiv H₂N-(CH₂)₅-COOH, 2 equiv DMAP, 1 equiv BOP, DMF, rt, 24 hours.

Scheme 3

Synthesis of hydroxamates 10a,b from betulinic acid. Reagents and conditions: (a) 2 equiv H₂N-(CH₂)₅-COOH, 2 equiv 4-dimethylaminopyridine (DMAP), 1 equiv BOP, dimethylformamide (DMF), room temperature (rt), 24 hours; (b) 2 equiv hydroxylammonium chloride, 1 equiv BOP, 2 equiv DMAP, DMF, rt, 15 hours; (c) 2 equiv N,O-dimethylhydroxylammonium chloride, 1 equiv BOP, 2 equiv DMAP, DMF, rt, 15 hours.

Finally, the synthesis of hydoxamates 15a,b is illustrated in Scheme 4. Dicarboxylic acid 11, isolated from Schefflera octophylla (Ivy tree),³⁰ was evaluated as the template for derivatization. Initial Jones oxidation (CrO₃) of acid 11 using sulfuric acid (H₂SO₄) in acetone resulted in the corresponding acid intermediate, which was subjected to decarboxylation to provide ketone 12 (Scheme 4). Next, reduction of 12 using sodium tetrahydroborate gave compound 13, which was then reacted with 6-aminohexanoic acid in the presence of a mixture BOP/DMAP (1:2) in DMF at room temperature for 24 hours to give the acid intermediate 14 (Scheme 4). Similarly, acids 6, 9, and 14 were treated with either NH₂OH.HCl or HNMeOMe.HCl under the same reaction conditions to afford the targeted compounds 15a,b in good yield. The structures of the products were determined by spectroscopic methods, such as ¹H nuclear magnetic resonance (NMR), ¹³C NMR, and infrared (IR), and mass spectrometry (MS) analysis.

Scheme 4

Synthesis of hydroxamates 15a,b. Reagents and conditions: (a) chromium trioxide, sulfuric acid, acetone, 0°C-room temperature (rt); (b) 4 equiv sodium borohydride, methanol, tetrahydrofuran, 0°C-rt, 10 hours; (c) 2 equiv H₂N-(CH₂)₅-COOH, 1 equiv BOP, 2 equiv 4-dimethylaminopyridine (DMAP), dimethylformamide (DMF), rt, 24 hours; (d) 2 equiv hydroxylammonium chloride, 2 equiv DMAP, 1 equiv BOP, DMF, rt, 15 hours; (e) 2 equiv N,O-dimethylhydroxylammonium chloride, 1 equiv BOP, 2 equiv DMAP, DMF, rt, 15 hours.

Biology

The newly prepared compounds were subjected to cytotoxic evaluation in order to assess their biological relevance. Betulin derived hydroxamates 3a-f, the 3β acetoxy-21-oxolup-18-ene-28-oic acid derived hydroxamates 5a,b, 7a,b, and the betulinic acid derived hydroxamates 10a,b, as well as the hydroxamates 15a,b were evaluated in vitro for their cytotoxic activity by using 3-[4,5-dimethylthiazol-2-yl]−2,5-diphenyltetrazolium bromide (MTT) assay against 2 human cancer cell lines (KB, HepG2); the results of these assays are summarized in Table 1. The results indicated that most of the tested derivatives possess at least moderate cytotoxic activity. Betulin derived hydroxamates 3c and 3e showed high cytotoxicity against both cell lines with half-maximal inhibitory concentration (IC₅₀) values ranging from 8.50 to 9.13 µM. In particular, compounds 7a and 15b showed good cytotoxicity against KB and HepG2 cell lines with IC₅₀ values of 3.06 µM and 4.22 µM for 7a, and 5.18 µM and 6.21 µM for 15b, respectively, pointing to the potential interest in this new class of hybrid molecules. However, comparing the cytotoxicity of compounds 3a, 3c, 5a, 7a, and 10a (RCONHOH) with compounds 3b, 3d, 5b, 7b, and 10b (RCONMeOMe), it is clear that the hydroxamic acid analogs 3a, 3c, 5a, 7a, and 10a exhibited more potent cytotoxic effects than the corresponding hydroxamates 3b, 3d, 5b, 7b, and 10b. In addition, comparing the cytotoxicity of hydroxamates via an ester bridge (3a, 3c) with hydroxamates via an amide bridge (7a, 15b) showed that the cytotoxicity of compounds 7a and 15b was higher than that of compounds 3a and 3c.

Table 1

Synthesis and Cytotoxicity of Synthesized Compounds.

Entry	Compounds (yield, %)	IC₅₀ (µM) KB	IC₅₀ (µM) HepG2
1	3a (57)	29.8	23.4
2	3b (63)	55.7	93.2
3	3c (61)	8.5	67.1
4	3d (61)	87.7	65.8
5	3e (63)	63.8	9.1
6	3f (62)	58.1	113.7
7	5a (59)	23.1	24.7
8	5b (60)	50.1	141.0
9	7a (53)	3.1	4.2
10	7b (64)	68.2	137.1
11	10a (61)	43.7	64.4
12	10b (65)	103.8	106.7
13	15a (54)	35.1	45.1
14	15b (71)	5.2	6.2
16	Ellipticine^a	1.3	1.5

IC₅₀, half-maximal inhibitory concentration.

^aPositive control compound.

Conclusion

To sum up, 14 new hydroxamate derivatives of lupane triterpenoids have been designed and successfully synthesized. The synthesized compounds were evaluated using the MTT-based assay against the 2 human cancer cell lines (KB and HepG2). The results indicate that most of these derivatives possess at least moderate cytotoxic activity and compounds 3 c, 3e, 7a, and 15b based hydroxamate derivatives could be lead compounds for further optimization to develop novel anticancer agents.

Experimental

General: Chemistry

The reagents were commercially available and used without further purification. Analytical thin-layer chromatography (TLC) was performed on HSGF 254 (0.15, 0.2 mm thickness). Melting points were measured on a Boetius apparatus and are uncorrected. Column chromatography was performed using silica gel (60 Å, particle size 40-60 µm). NMR spectra were recorded on a BrukerAvance (500 MHz) spectrophotometer. Chemical shifts (δ) are given in parts per million (ppm) and coupling constants (J) in Hertz (Hz). Liquid chromatography (LC)–MS analysis was conducted on a Q-Exactive focus instrument. IR spectra were obtained using a Spectrum Two Perkin Elmer spectrophotometer using Nujol and potassium bromide (KBr) pellets.

Syntheses

General procedure for preparation of conjugates between the triterpenoid and NH₂OH.HCl and HNMeOMe.HCl 3a-f, 5a,b, 7a,b, 10a,b, and 15a,b

To a solution of the corresponding acid 2a-d, 4, 6, 9, and 14 (1.0 mmol) in DMF (5 mL) was added BOP (1.0 mmol) and DMAP (2.0 mmol); the mixture was stirred for 5-10 min at room temperature. NH₂OH.HCl (or HNMeOMe.HCl) (2.0 mmol) was then added, and the mixture stirred at room temperature until the starting material had been consumed completely (15 hours). Afterward, water was added to the mixture, which was acidified to pH 5 with a solution of HCl 10% to induce precipitation. The crystals were removed by filtration and washed with water. The crude product was redissolved in ethyl acetate (EtOAC, 20 mL) to which water (20 mL) was added. The aqueous phase was extracted with EtOAc (20 mL × 3). Drying (sodium sulfate), filtration of the drying agent, and removal of the solvent in vacuo afforded targeted conjugates 3a-f, 5a,b, 7a,b, 10a,b, and 15a,b respectively, which were further purified by column chromatography on silica gel using methanol in dichloromethane (0%-10%).

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 4-(hydroxyamino)-4-oxobutanoate (3a)

White solid. Yield 57%.

Mp: 227-229^oC.

IR (KBr) cm⁻¹: 3367, 2958, 2879, 1706, 1698, 1567, 1454, 1367, 1251, 1138, 1093, 883.

¹H NMR (500 MHz, dimethylsulfoxide [DMSO]-d ₆) δ (ppm): 10.39 (1H, s), 8.69 (1H, s), 4.69 (1H, s), 4.55 (1H, s), 4.27 (1H, d, J = 11.0 Hz), 4.25 (1H, d, J = 11.0 Hz), 3.75 (1H, d, J = 11.5 Hz), 2.97-2.94 (1H, m), 2.23 (2H, t, J = 7.5 Hz), 1.93-1.89 (1H, m), 1.72-1.70 (2H, m), 1.64-1.59 (5H, m), 1.56-1.53 (2H, m), 1.46-1.42 (2H, m), 1.36-1.29 (5H, m), 1.25-1.16 (6H, m), 1.07-1.05 (2H, m), 1.03 (3H, s), 0.97 (3H, s), 0.93 (3H, s), 0.87 (3H, s), 0.76 (3H, s).

¹³C NMR (125 MHz, DMSO-d ₆) δ (ppm): 172.8, 168.3, 150.1, 110.2, 89.4, 77.2, 55.1, 50.4, 48.8, 47.3, 46.3, 42.4, 40.6, 39.1, 39.0, 38.7, 38.5, 37.3, 36.9, 34.3, 34.1, 29.4, 29.1, 28.3, 27.2, 26.8, 25.0, 20.5, 19.0, 18.2, 16.1, 16.0, 15.9, 14.7.

LC–MS/MS: Found m/z 558.3437 [M + H]⁺, Calc. for C₃₄H₅₅NO₅: 558.3458.

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 4-(methoxy(methyl)amino)-4-oxobutanoate (3b)

White solid. Yield 63%.

Mp: 237-239°C.

IR (KBr) cm⁻¹: 2940, 2869, 1733, 1667, 1534, 1455, 1360, 1278, 1174, 1045, 883.

¹H NMR (500 MHz, deuterated chloroform [CDCl₃]) δ (ppm): 4.68 (1H, s), 4.58 (1H, s), 4.27 (1H, d, J = 11.0 Hz), 3.89 (1H, d, J = 11.0 Hz), 3.72 (3H, s), 3.17 (3H, s), 2.76 (2H, s), 2.70-2.66 (2H, m), 2.45-2.41 (1H, m), 1.98-1.94 (1H, m), 1.86-1.83 (1H, m), 1.80-1.75 (2H, m), 1.71-1.53 (7H, m), 1.42-1.39 (4H, m), 1.27-1.24 (6H, m), 1.02 (3H, s), 0.98 (3H, s), 0.96 (3H, s), 0.84 (3H, s), 0.76 (3H, s).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 173.3, 171.1, 150.2, 109.7, 78.9, 62.8, 61.2, 55.3, 50.3, 48.8, 47.7, 46.3, 42.7, 40.8, 38.8, 38.7, 37.6, 37.1, 34.5, 34.2, 29.8, 29.7, 29.6, 28.7, 27.9, 27.3, 27.1, 25.2, 20.8, 19.1, 18.3, 16.1, 16.0, 15.3, 14.7, 14.2.

LC–MS/MS: Found m/z 586.2869 [M + H]⁺, Calc. for C₃₆H₅₉NO₅: 586.2866.

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 5-(hydroxyamino)-5-oxopentanoate (3c)

White solid. Yield 61%.

Mp: 217-219^oC.

IR (KBr) cm⁻¹: 3329, 2987, 2876, 1743,1697, 1561, 1455, 1389, 1238, 1109, 1087, 776.

¹H NMR (500 MHz, DMSO-d ₆) δ (ppm): 10.35 (1H, s), 8.69 (1H, s), 4.69 (1H, s), 4.55 (1H, s), 4.27 (1H, d, J = 11.0 Hz), 3.85 (1H, d, J = 11.0 Hz), 3.76 (2H, s), 3.34 (2H, m), 2.76 (2H, m), 2.73-2.67 (1H,m), 2.45-2.42 (4H, m), 1.97-1.93 (2H, m), 1.85-1.82 (1H, m), 1.81-1.74 (2H, m), 1.70-1.51 (6H, m), 1.41-1.37 (4H, m), 1.68 (3H, s), 1.02 (3H, s), 0.97 (3H, s), 0.93 (3H, s), 0.87 (3H, s), 0.78 (3H, s), 0.68-0.67 (1H, m).

¹³C NMR (125 MHz, DMSO-d ₆) δ (ppm): 172.3, 171.6, 150.1, 109.3, 77.9, 62.5, 60.2, 54.2, 51.3, 48.7, 47.2, 46.4, 41.7, 40.3, 37.8, 38.6, 36.5, 37.1, 34.3, 34.1, 29.7, 29.5, 29.2, 28.7, 27.6, 27.4, 27.1, 25.3, 20.7, 19.2, 18.5, 16.7, 16.0, 15.2, 14.6, 14.3.

LC–MS/MS: Found m/z 572,4257 [M + H]⁺, Calc. for C₃₅H₅₇NO₅: 572,4237.

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 5-(methoxy(methyl)amino)-5-oxopentanoate (3d)

White solid. Yield 61%.

Mp: 223-225^oC.

IR (KBr) cm⁻¹: 2939, 2868, 1723, 1641, 1557, 1403, 1359, 1260, 1193, 1087, 878.

¹H NMR (500 MHz, CDCl₃) δ (ppm): 4.68 (1H, s), 4.58 (1H, s), 4.26 (1H, d, J = 11,0 Hz), 3.86 (1H, d, J = 11.0 Hz), 3.67 (3H, s), 3.17 (3H, s), 2.49 (2H, t, J = 7.5 Hz), 2.42 (3H, t, J = 7.5 Hz), 1.95 (3H, t, J = 8,0 Hz), 1.85-1.84 (1H, m), 1.82-1.81 (1H, m), 1.67-1.58 (6H, m), 1.56-1.51 (2H, m), 1.42-1.36 (5H, m), 1.28-1.16 (6H, m), 1.10-1.05 (2H, m), 1.03 (3H, s), 0.97 (3H, s), 0.96 (3H, s), 0.82 (3H, s), 0.76 (3H, s), 0.68-0.66 (1H, m).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 174.2, 173.6, 150.1, 109.8, 78.9, 62.6, 61.2, 55.3, 50.4, 48.8, 47.7, 46.4, 42.7, 40.9, 38.8, 38.7, 38.6, 37.6, 37.1, 34.5, 34.2, 33.7, 30.9, 29.8, 29.6, 27.9, 27.4, 27.1, 25.2, 20.8, 19.9, 19.1, 18.3, 16.1, 16.0, 15.3, 14.7.

LC–MS/MS: Found m/z 600.3534 [M + H]⁺, Calc. for C₃₇H₆₁NO₅: 600.3523.

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 4-(methoxy(methyl)amino)-3-methyl-4-oxobutanoate (3e)

White solid. Yield 63%.

Mp: 229-231^oC.

IR (KBr) cm⁻¹: 2939, 2869, 1732, 1668, 1553, 1460, 1384, 1224, 1176, 1046, 880.

¹H NMR (500 MHz, CDCl₃) δ (ppm): 4.67 (1H, s), 4.58 (1H, s), 4.34 (1H, d, J = 11.0 Hz), 4.21 (1H, d, J = 11.0 Hz), 3.94 (1H, d, J = 7.5 Hz), 3.66 (3H, m), 3.17 (3H, s), 3.05-2.99 (1H, m), 2.93-2.88 (1H, m), 2.51-2.41 (2H,m), 1.97-1.82 (1H, m), 1.76-1.71 (2H, m), 1.67-1.56 (6H, m), 1.54-1.51 (2H, m), 1.42-1.36 (5H, m), 1.28-1.18 (6H, m), 1.09 (3H, d, J = 6.0 Hz), 1.07 (3H, s), 0.97 (3H, s), 0.96 (3H, s), 0.84 (3H, s), 0.77 (3H, s).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 176.3, 175.7, 150.2, 109.7, 79.0, 62.7, 61.1, 55.3, 51.8, 50.4, 48.9, 47.7, 46.6, 42.7, 40.9, 38.8, 38.7, 37.6, 37.1, 35.4, 34.5, 34.2, 29.8, 29.7, 27.9, 27.4, 27.1, 25.2, 20.8, 19.1, 18.3, 17.4, 17.3, 16.1, 16.0, 15.3, 14.7.

LC–MS/MS: Found m/z 600.4641 [M + H]⁺, Calc. for C₃₇H₆₁NO₅: 600.4626.

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 6-(methoxy(methyl)carbamoyl)cyclohex-3-ene-1-carboxylate (3f)

White solid. Yield 62%.

Mp: 217-219^oC.

IR (KBr) cm⁻¹: 3074, 2963, 2866, 1733, 1711, 1510, 1454, 1384, 1291, 1185, 1020, 881.

¹H NMR (500 MHz, CDCl₃) δ (ppm): 5.76-5.74 (1H, m), 5.68-5.65 (1H, m), 4.67 (1H, s), 4.57 (1H, s), 3.90-3.83 (1H, m), 3.74 (3H, s), 3.40-3.36 (1H, m), 3.16 (3H, s), 2.95-2.88 (1H, m), 2.81-2.73 (1H, m), 2.42-2.37 (4H, m), 2.04 (1H, s), 1.97-1.94 (1H, m), 1.86-1.77 (2H, m), 1.71-1.64 (5H, m), 1.62-1.51 (4H, m), 1.42-1.34 (3H, m), 1.29=1.24 (6H, m), 1.03=1.01 (3H, m), 0.96 (6H, s), 0.91=0.86 (3H, m), 0.81 (3H, s), 0.75 (3H, s), 0.68-0.67 (1H, m).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 174.4, 174.3, 150.2, 125.5, 124.9, 109.7, 78.9, 62.8, 55.3, 50.4, 48.8, 47.7, 46.3, 42.7, 40.8, 39.9, 39.6, 38.7, 37.6, 37.1, 35.8, 35.6, 34.5, 29.8, 29.7, 29.6, 27.9, 27.4, 27.1, 27.0, 26.2, 26.1, 25.2, 19.1, 18.3, 16.1, 16.0, 15.3, 14.7, 14.2.

LC–MS/MS: Found m/z 638.4221 [M + H]⁺, Calc. for C₄₀H₆₃NO₅: 638.4279.

(3aR,5aR,5bR,11aR)-3a-(hydroxycarbamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]- chrysen-9-yl acetate (5a)

White solid. Yield 59%.

Mp: 203-205 ^oC.

IR (KBr) cm⁻¹: 3435, 2948, 2856, 1735, 1647,1673, 1381, 1246, 1025, 825.

¹H NMR (500 MHz, DMSO-d ₆) δ (ppm): 10.31 (1H, s), 8.75 (1H, s), 4.38 (1H, dd, J = 11.5, 5.0 Hz), 3.17-3.12 (1H, m), 2.74 (1H, d, J = 11.0 Hz), 2.44 (1H, d, J = 13.5 Hz), 2.20-2.05 (2H, m), 1.99 (4H, s), 1.84-1.80 (1H, m), 1.70-1.60 (2H, m), 1.55-1.53 (2H, m), 1.47-1.38 (2H, m), 1.35-1.31 (3H, m), 1.25-1.23 (2H, m), 1.17 (5H, d, J = 6.5 Hz), 1.10 (3H, d, J = 6.5 Hz), 1.06-1.02 (3H, m), 0.98 (3H, s), 0.88 (3H, s), 0.83 (3H, s), 0.84-0.82 (1H, m), 0.79 (6H, s).

¹³C NMR (125 MHz, DMSO-d ₆) δ (ppm): 206.5, 171.9, 170.3, 170.0, 145.3, 79.8, 54.5, 51.7, 50.2, 48.1, 44.7, 44.4, 39.0, 37.8, 37.3, 36.6, 34.3, 33.1, 28.7, 27.6, 26.9, 24.6, 23.3, 20.9, 20.8, 20.1, 19.7, 17.6, 16.5, 16.4, 16.3, 15.6.

LC–MS/MS: Found m/z 528.4064 [M + H]⁺, Calc. for C₃₂H₄₉NO₅: 528.4089.

(3aR,5aR,5bR,11aR)-1-isopropyl-3a(methoxy(methyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (5b)

White solid. Yield 60%.

Mp: 237-239^oC.

IR (KBr) cm⁻¹: 2940, 2876, 1731, 1698, 1660, 1455, 1365, 1246, 1106, 1024, 869.

¹H NMR (500 MHz, CDCl₃) δ (ppm): 4.48 (1H, dd, J = 11.5, 5.0 Hz), 3.44 (3H, s), 3.21-3.18 (1H, m), 3.17 (3H, s), 2.63 (2H, dd, J = 12.5, 3.0 Hz), 2.50 (1H, d, J = 19.0 Hz), 2.10-2.01 (6H, m), 1.90-1.87 (1H, m), 1.75-1.72 (1H, m), 1.69-1.64 (2H, m), 1.62-1.59 (2H, m), 1.541.52 (1H, m), 1.481.45 (1H, m), 1.391.33 (3H, m), 1.251.23 (6H, m), 1.211.16 (2H, m), 1.061.05 (1H, m-), 1.03 (3H, s), 0.98 (3H, s), 0.90 (3H, s), 0.83 (5H, s), 0.80 (3H, s).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 207.4, 174.7, 174.2, 171.0, 142.8, 80.7, 61.1, 55.4, 53.7, 51.2, 47.0, 46.2, 45.7, 41.5, 38.6, 37.8, 37.1, 36.5, 34.9, 33.9, 29.1, 27.9, 27.3, 25.2, 23.6, 21.4, 21.2, 20.2, 20.0, 18.1, 16.8, 16.7, 16.5, 16.0.

LC–MS/MS: Found m/z 556.5251 [M + H]⁺, Calc. for C₃₄H₅₃NO₅: 556.5202.

(3aR,5aR,5bR,9S,11aR)-3a-((6-(hydroxyamino)−6-oxohexyl)carbamoyl)−1-isopropyl-5a,5b,8,8,11ª-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopen-ta[a]chrysen-9-yl acetate (7a)

White solid. Yield 53%.

Mp: 214-216^oC.

IR (KBr) cm⁻¹: 3259, 2946, 2872, 1735, 1693, 1685, 1674, 1527, 1456, 1378, 1245, 1106, 1027, 731.

¹H NMR (500 MHz, DMSO-d ₆) δ (ppm): 10.30 (1H, s), 8.61 (1H, s), 7.37 (1H, t, J = 5.5 Hz), 4.38 (1H, dd, J = 12.0, 5.0 Hz), 3.16 (1H, t, J = 8.5 Hz), 3.09 (1H, t, J = 6.5 Hz), 3.01 (1H, t, J = 7.0 Hz), 2.75 (1H, dd, J = 13.0, 2.5 Hz), 2.44 (1H, d, J = 12.5 Hz), 2.18-2.04 (2H, m), 1.99 (3H, s), 1.92 (3H, t, J = 8.0 Hz), 1.88-1.81 (1H, m), 1.71-1.59 (2H, m), 1.62-1.52 (3H, m), 1.47 (3H, t, J = 8.0 Hz), 1.40-1.33 (5H, m), 1.29-1.20 (5H, m), 1.17 (4H, d, J = 7.0 Hz), 1.11 (4H, d, J = 7.0 Hz), 1.07-1.02 (3H, m), 0.95 (3H, s), 0.88 (3H, s), 0.85 (3H, s), 0.79 (6H, s).

¹³C NMR (125 MHz, DMSO-d ₆) δ (ppm): 206.9, 173.1, 172.8, 170.1, 168.9, 144.9, 89.1, 79.8, 54.8, 54.5, 52.8, 50.1, 47.9, 44.7, 44.3, 40.8, 38.6, 37.8, 37.3, 36.6, 34.2, 32.1, 28.9, 28.6, 27.6, 26.9, 26.1, 24.9, 24.5, 23.3, 20.9, 20.1, 19.9, 17.6, 16.5, 16.4, 16.2, 15.5.

LC–MS/MS: Found m/z 641.4489 [M + H]⁺, Calc. for C₃₈H₆₀N₂O₆: 641.4429.

(3aR,5aR,5bR,11aR)-1-isopropyl-3a-((6-(methoxy(methyl)ami-no)−6-oxohexyl)carbamoyl)−5a,5b, 8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (7b)

White solid. Yield 64%.

Mp: 223-225^oC.

IR (KBr) cm⁻¹: 3328, 2927, 2853, 1719, 1669, 1695, 1628, 1512, 1452, 1378, 1252, 1186, 1086, 894.

¹H NMR (500 MHz, CDCl₃) δ (ppm): 7.43 (1H, t, J = 5.5 Hz), 4.47 (1H, dd, J = 11.0, 5.5 Hz), 3.67 (3H, s), 3.48-3.46 (1H, m), 3.34-3.46 (1H, m), 3.25 (1H, t, J = 7.0 Hz), 3.17 (3H, s), 2.71-2.68 (1H, m), 2.67-2.60 (1H, m), 2.41 (2H, t, J = 9.0 Hz), 2.17-2.13 (1H, m), 2.04 (3H, s), 1.95-1.91 (3H, m), 1.82-1.86 (1H, m), 1.73-1.59 (5H, m), 1.53-1.47 (3H, m), 1.39-1.28 (5H, m), 1.25-1.22 (6H, m), 1.13-1.05 (3H, m), 1.02 (3H, s), 0.93 (3H, s), 0.90 (3H, s), 0.85 (3H, s), 0.84 (3H, s), 0.81-0.79 (1H, m).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 207.5, 173.4, 173.0, 171.0, 156.8, 147.6, 89.6, 80.7, 61.2, 55.4, 53.6, 51.0, 49.2, 45.4, 45.3, 41.4, 39.4, 38.6, 37.8, 37.1, 34.8, 33.9, 33.0, 29.7, 29.3, 27.4, 26.5, 25.6, 25.3, 24.9, 23.9, 23.6, 21.3, 20.5, 19.9, 18.1, 16.8, 16.7, 16.5, 15.9.

LC–MS/MS: Found m/z 669.3528 [M + H]⁺, Calc. for C₄₀H₆₄N₂O₆: 669.3538.

(1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-N-(6-(hydroxyamino)-6-oxohexyl)−5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosa-hydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (10a)

White solid. Yield 61%.

Mp: 276-278 ^oC.

IR (KBr) cm⁻¹: 3386, 3081, 2940, 2866, 1707, 1636, 1530, 1452, 1375, 1247, 1194, 1043, 847.

¹H NMR (500 MHz, DMSO-d ₆) δ (ppm): 10.27 (1H, s), 8.57 (1H, s), 7.46 (1H, t, J = 5.0 Hz), 4.65 (1H, s), 4.17 (1H, d, J = 5.0 Hz), 3.09-2.91 (3H, m), 2.12 (2H, d, J = 11.0 Hz), 1.92 (2H, t, J = 7.0 Hz), 1.77-1.70 (3H, m), 1.62 (5H, s), 1.57 (1H, t, J = 13.0 Hz), 1.49-1.40 (5H, m), 1.37-1.27 (6H, m), 1.26-1.22 (3H, m), 1.17-1.14 (2H, m), 1.04-1.01 (2H, m), 0.93 (3H, s), 0.90 (3H, s), 0.87 (3H, s), 0.84 (3H, s), 0.81 (3H, s), 0.65 (3H, s).

¹³C NMR (125 MHz, DMSO-d ₆) δ (ppm): 175.7, 169.5, 151.1, 144.1, 109.6, 89.6, 77.3, 55.4, 55.3, 50.1, 46.6, 42.4, 40.7, 38.9, 38.7, 38.2, 37.2, 37.1, 34.5, 32.7, 30.8, 29.5, 29.3, 28.6, 27.6, 26.5, 25.7, 25.3, 21.0, 19.5, 18.4, 16.4, 16.3, 16.2, 14.8.

LC–MS/MS: Found m/z 585.4596 [M + H]⁺, Calc. for C₃₆H₆₀N₂O₄: 585.4553.

(1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-N-(6-(methoxy(methyl)-amino)−6-oxohexyl)−5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (10b)

White solid. Yield 65%.

Mp: 229-231^oC.

IR (KBr) cm⁻¹: 3371, 2934, 2864, 1697, 1638, 1530, 1463, 1388, 1247, 1193, 1082, 882.

¹H NMR (500 MHz, CDCl₃) δ (ppm): 5.72 (1H, t, J = 5.0 Hz), 4.73 (1H, s), 4.58 (1H, s), 3.67 (3H, s), 3,29 (1H, t, J = 6.5 Hz), 3.17 (3H, s), 3.16–3.11 (′1H, m), 2.42 (3H, t, J = 8.0 Hz), 1.97-1.91 (3H, m), 1.74-1.72 (2H, m), 1.71 (6H, s), 1.55-1.47 (6H, m), 1.41-1.28 (6H, m), 1.25 (6H, s), 1.14-1.12 (2H, m), 0.96 (6H, s), 0.93 (3H, s), 0.89-0.86 (3H, m), 0.81 (3H, s), 0.75 (3H, s), 0.68-0.66 (1H, m).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 177.1, 176.2, 151.0, 109.2, 78.9, 61.1, 55.6, 55.4, 50.7, 50.2, 46.7, 42.5, 40.8, 38.9, 38.8, 38.4, 37.7, 37.2, 34.4, 33.9, 33.8, 30.9, 29.6, 29.5, 29.4, 28.0, 27.4, 26.6, 25.6, 24.9, 24.0, 20.1, 19.5, 18.3, 16.2, 16.1, 15.3, 14.6.

LC–MS/MS: Found m/z 613.3348 [M + H]⁺, Calc. for C₃₈H₆₄N₂O₄: 613.3339.

(1R,3aS,5aR,5bR,8R,9S,11aS)-9-hydroxy-N-(6-(hydroxyamino)-6-oxohexyl)-5a,5b,8,11a-tetrame-thyl-1-(prop-1-en-2-yl)icosa-hydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (15a)

White solid. Yield 54%.

Mp: 205-207^oC.

IR (KBr) cm⁻¹: 3362, 2976, 2953, 1714, 1687, 1538, 1475, 1321, 1269, 1108, 1089, 765.

¹H NMR (500 MHz, DMSO-d ₆) δ (ppm): 10.30 (1H, s), 8.61 (1H, s), 7.50 (1H, t, J = 5.0 Hz), 4.64 (1H, s), 4.53 (1H, s), 4.28 (1H, d, J = 6.0 Hz), 3.07-3.00 (3H, m), 2.12 (2H, m), 1.92 (2H, t, J = 7.0 Hz), 1.75-1.70 (3H, m), 1.62 (3H, s), 1.48-1.42 (7H, m), 1.33 (3H, s), 1.23 (3H, s), 1.89 (3H, s), 1.16 (3H, s), 1.12-0.98 (2H, m), 0.90 (6H, s), 0.83 (3H, s), 0.79 (3H, d, J = 1.5 Hz), 0.65 (3H, s).

LC–MS/MS: Found m/z 571.4433 [M + H]⁺, Calc. for C₃₅H₅₈N₂O₄: 571.4471.

(1R,3aS,5aR,5bR,8R,9S,11aS)-9-hydroxy-N-(6-(methoxy(me-thyl)amino)−6-oxohexyl)−5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (15b)

White solid. Yield 71%.

Mp: 224-226^oC.

IR (KBr) cm⁻¹: 3374, 2933, 2866, 1697, 1637, 1530, 1452, 1375, 1296, 1198, 1040, 882.

¹H NMR (500 MHz, CDCl₃) δ (ppm): 5.67 (1H, t, J = 5.5 Hz), 4.73 (1H, s), 4.58 (1H, s), 3.67 (3H, s), 3.29 (1H, t, J = 6.5 Hz), 3.17 (3H, s), 3.07-3.02 (1H, m), 2.42 (3H, t, J = 7.0 Hz), 1.96-1.91 (2H, m), 1.78-1.70 (3H, m), 1.68 (6H, s), 1.62-1.47 (9H, m), 1.42-1.28 (6H, m), 1.25 (6H, s), 1.17-1.13 (2H, m), 0.96 (3H, s), 0.93 (3H, s), 0.89 (3H, s), 0.87 (3H, d, J = 1.5 Hz), 0.77 (3H, s), 0.61-0.65 (1H, m).

¹³C NMR (125 MHz, CDCl₃) δ (ppm): 177.1, 176.0, 151.0, 109.2, 76.8, 61.2, 55.6, 51.4, 50.2, 48.6, 46.8, 42.5, 40.4, 38.9, 38.5, 38.4, 38.0, 37.7, 36.5, 33.8, 33.5, 31.7, 30.9, 30.7, 29.7, 29.6, 29.3, 26.7, 25.4, 24.0, 21.3, 20.8, 19.5, 16.2, 15.0, 14.5, 14.0.

LC–MS/MS: Found m/z 559.3259 [M + H]⁺, Calc. for C₃₇H₆₂N₂O₄: 559.3283.

General: Biological Screening

Two human cancer cell lines (epidermoid carcinoma cell line KB-ATCC CCL-17 and hepatoma carcinoma cell line HepG2-ATCC HB-8065), obtained from the American Type Culture Collection (USA) ATCC, were used for cytotoxic evaluation. The cells were grown in Roswell Park Memorial Institute Medium 1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere (95% air and 5% carbon dioxide). The exponentially growing cells were used throughout the experiments. The inhibitory effects of the compounds on the growth of the human cancer cell lines were determined by measuring the metabolic activity using an MTT assay. Briefly, human cancer cell lines (1 × 10⁵ cells/mL) were treated for 3 days with a series of concentrations of the compounds (in DMSO): 0.125, 0.5, 2.0, 8.0, 32.0, and 128.0 µg/mL. After incubation, 0.1 mg MTT solution (50 µL of a 2 mg/mL solution) was added to each well, and the cells were then incubated at 37°C for 4 hours. The plates were centrifuged at 1000 rpm for 10 minutes at room temperature, and the media were then carefully aspirated. DMSO (150 µL) was added to each well to dissolve the formazan crystals. The plates were read immediately at 540 nm on a microplate reader (TECAN GENIOUS). All the experiments were performed 3 times, and the mean absorbance values were calculated. The results are expressed as the percentage of inhibition that produced a reduction in the absorbance by the treatment of the compounds compared with the untreated controls. A dose–response curve was generated, and the IC₅₀ value was determined for each compound as well as each cell line.

Supplemental Material

Figure S1 - Supplemental material for Design, Synthesis, and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates

Supplemental material, Figure S1, for Design, Synthesis, and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates by Dang Thi Tuyet Anh, Dinh Thi Cuc, Le Nhat Thuy Giang, Nguyen Thi Hien, Vu Ngoc Doan, Nguyen Ha Thanh, Nguyen Van Tuyen and Phan Van Kiem in Natural Product Communications

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors are indebted to Vietnam Academy of Science and Technology (VAST, code: NVCC06.01/20-20) for financial support.

ORCID iD

Phan Van Kiem

References

World Health Organization . Available online. www.who/int/health-topic/cancer

Aggarwal

Jha

Shrivastava

Jha

. Natural compounds: role in reversal of epigenetic changes. Biochemistry. 2015;80(8):972-989.doi:10.1134/S0006297915080027

http://www.ncbi.nlm.nih.gov/pubmed/26547065

Nordgren

KK.

Skildum

. The deep end of the metabolite pool: influences on epigenetic regulatory mechanisms in cancer. Eur J Clin Invest. 2015;45(Suppl 1):9-15.doi:10.1111/eci.12361

http://www.ncbi.nlm.nih.gov/pubmed/25524581

Ushijima

. Cancer epigenetics: now harvesting fruit and seeding for common diseases. Biochem Biophys Res Commun. 2014;455(1-2):1-2.doi:10.1016/j.bbrc.2014.11.008

http://www.ncbi.nlm.nih.gov/pubmed/25434294

Jones

PA.

Baylin

. The epigenomics of cancer. Cell. 2007;128(4):683-692.doi:10.1016/j.cell.2007.01.029

http://www.ncbi.nlm.nih.gov/pubmed/17320506

Bird

epigenetics

Pof

. Perceptions of epigenetics. Nature. 2007;447(7143):396-398.doi:10.1038/nature05913

http://www.ncbi.nlm.nih.gov/pubmed/17522671

pp. Russo

VEA.

Martienssen

RA.

Riggs

. Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press; 1996:13-30.

Weichert

Röske

Gekeler

et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9(2):139-148.doi:10.1016/S1470-2045(08)70004-4

http://www.ncbi.nlm.nih.gov/pubmed/18207460

Weichert

. Hdac expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168-176.doi:10.1016/j.canlet.2008.10.047

http://www.ncbi.nlm.nih.gov/pubmed/19103471

10.

Weichert

Denkert

Noske

et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008;10(9):1021-1027.doi:10.1593/neo.08474

http://www.ncbi.nlm.nih.gov/pubmed/18714364

11.

Song

Noh

JH.

Lee

et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005;113(4):264-268.doi:10.1111/j.1600-0463.2005.apm_04.x

http://www.ncbi.nlm.nih.gov/pubmed/15865607

12.

Fritzsche

FR.

Weichert

Röske

et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8:38110.1186/1471-2407-8-381

http://www.ncbi.nlm.nih.gov/pubmed/19099586

doi:10.1186/1471-2407-8-381

13.

Weichert

Röske

Gekeler

et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98(3):604-610.doi:10.1038/sj.bjc.6604199

http://www.ncbi.nlm.nih.gov/pubmed/18212746

14.

Souza

Chatterji

. Hdac inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer Drug Discov. 2015;10(2):145-162.doi:10.2174/1574892810666150317144511

http://www.ncbi.nlm.nih.gov/pubmed/25782916

15.

Schmudde

Braun

Pende

et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008;272(1):110-121.doi:10.1016/j.canlet.2008.06.027

http://www.ncbi.nlm.nih.gov/pubmed/18718708

16.

Steward

WP.

Thomas

. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs. 2000;9(12):2913-2210.1517/13543784.9.12.2913

http://www.ncbi.nlm.nih.gov/pubmed/11093361

doi:10.1517/13543784.9.12.2913

17.

Marmion

CJ.

Griffith

Nolan

. Hydroxamic acids − an intriguing family of enzyme inhibitors and biomedical ligands. Eur J Inorg Chem. 2004;15:3003-3016.

18.

Mottamal

Zheng

Huang

TL.

Wang

. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20(3):3898-3941.doi:10.3390/molecules20033898

http://www.ncbi.nlm.nih.gov/pubmed/25738536

19.

Fenichel

. Fda approves new agent for multiple myeloma. J Natl Cancer Inst. 2015;107(6):djv165-167.doi:10.1093/jnci/djv165

http://www.ncbi.nlm.nih.gov/pubmed/26032612

20.

Poole

. Belinostat: first global approval. Drugs. 2014;74(13):1543-1554.doi:10.1007/s40265-014-0275-8

http://www.ncbi.nlm.nih.gov/pubmed/25134672

21.

Cai

Zhai

H-X.

Wang

et al. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 2010;53(5):2000-2009.doi:10.1021/jm901453q

http://www.ncbi.nlm.nih.gov/pubmed/20143778

22.

Marks

PA.

Dokmanovic

. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14(12):1497-511-1511.doi:10.1517/13543784.14.12.1497

http://www.ncbi.nlm.nih.gov/pubmed/16307490

23.

Glaser

. Hdac inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659-671.doi:10.1016/j.bcp.2007.04.007

http://www.ncbi.nlm.nih.gov/pubmed/17498667

24.

Dang

Zhu

et al. New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. J Med Chem. 2013;56(5):2029-2037.doi:10.1021/jm3016969

http://www.ncbi.nlm.nih.gov/pubmed/23379607

25.

Hill

RA.

Connolly

JD.

Robert

AH.

Triterpenoids

JDC

. Triterpenoids. Nat Prod Rep. 2018;35(12):1294-1329.doi:10.1039/C8NP00029H

http://www.ncbi.nlm.nih.gov/pubmed/29993074

26.

Rashid

Dar

BA.

Majeed

Hamid

Bhat

. Synthesis and biological evaluation of ursolic acid-triazolyl derivatives as potential anti-cancer agents. Eur J Med Chem. 2013;66(238-245):238-245.doi:10.1016/j.ejmech.2013.05.029

http://www.ncbi.nlm.nih.gov/pubmed/23811086

27.

Eiznhamer

DA.

Z-Q

. Betulinic acid: a promising anticancer candidate. IDrugs. 2004;7(4):359-373.http://www.ncbi.nlm.nih.gov/pubmed/15057642

28.

Zhao

Pawlak

et al. Antitumor activity of betulinic acid and betulin in canine cancer cell lines. In Vivo. 2018;32(5):1081-1088.doi:10.21873/invivo.11349

http://www.ncbi.nlm.nih.gov/pubmed/30150429

29.

Dang

TTA.

Le NTG

NTH

et al. Synthesis and cytotoxic evaluation of novel ester derivatives of botulin with AZT, D4T, and 3TC. Nat Prod Commun. 2017;12(6):885-888.

30.

Tran

VL.

Tran

VS.

Kamperdick

et al. Synthesis of amino acid conjugates and further derivatives of 3α-hydroxylup-20(29)-ene-23,28-dioic acid. J für praktische Chemie. 2000;3:42-63.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

2.90 MB

0.00 MB

Design,Synthesis,and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates

Abstract

Keywords

Introduction

Results and Discussion

Chemistry

Biology

Conclusion

Experimental

General: Chemistry

Syntheses

General procedure for preparation of conjugates between the triterpenoid and NH2OH.HCl and HNMeOMe.HCl 3a-f, 5a,b, 7a,b, 10a,b, and 15a,b

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 4-(hydroxyamino)-4-oxobutanoate (3a)

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 4-(methoxy(methyl)amino)-4-oxobutanoate (3b)

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 5-(hydroxyamino)-5-oxopentanoate (3c)

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 5-(methoxy(methyl)amino)-5-oxopentanoate (3d)

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 4-(methoxy(methyl)amino)-3-methyl-4-oxobutanoate (3e)

((1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl 6-(methoxy(methyl)carbamoyl)cyclohex-3-ene-1-carboxylate (3f)

(3aR,5aR,5bR,11aR)-3a-(hydroxycarbamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]- chrysen-9-yl acetate (5a)

(3aR,5aR,5bR,11aR)-1-isopropyl-3a(methoxy(methyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (5b)

(3aR,5aR,5bR,9S,11aR)-3a-((6-(hydroxyamino)−6-oxohexyl)carbamoyl)−1-isopropyl-5a,5b,8,8,11ª-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopen-ta[a]chrysen-9-yl acetate (7a)

(3aR,5aR,5bR,11aR)-1-isopropyl-3a-((6-(methoxy(methyl)ami-no)−6-oxohexyl)carbamoyl)−5a,5b, 8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (7b)

(1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-N-(6-(hydroxyamino)-6-oxohexyl)−5a,5b,8,8,11a-pentame-thyl-1-(prop-1-en-2-yl)icosa-hydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (10a)

(1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-N-(6-(methoxy(methyl)-amino)−6-oxohexyl)−5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (10b)

(1R,3aS,5aR,5bR,8R,9S,11aS)-9-hydroxy-N-(6-(hydroxyamino)-6-oxohexyl)-5a,5b,8,11a-tetrame-thyl-1-(prop-1-en-2-yl)icosa-hydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (15a)

(1R,3aS,5aR,5bR,8R,9S,11aS)-9-hydroxy-N-(6-(methoxy(me-thyl)amino)−6-oxohexyl)−5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxamide (15b)

General: Biological Screening

Supplemental Material

Figure S1 - Supplemental material for Design, Synthesis, and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates

Footnotes

Declaration of Conflicting Interests

Funding

ORCID iD

References

Supplementary Material

General procedure for preparation of conjugates between the triterpenoid and NH₂OH.HCl and HNMeOMe.HCl 3a-f, 5a,b, 7a,b, 10a,b, and 15a,b